Little Pharma PDF Download

Author: Laura Kolbe
Publisher: University of Pittsburgh Press
ISBN: 0822988623
Category : Poetry
Languages : en
Pages : 140

View

Book Description
The title Little Pharma is both a doppelgänger and a cri de coeur: as the poet’s dreamlike double, the character Little Pharma navigates the murky channels of the hospital and clinic, the borderlands of the living and the dead, and the journey from novice to healer. At the same time, the poems plead for a return to a littler pharma, a space for stolen intimacy and momentary quiet amid the impersonal and engulfing chill that floods the anatomical theater and the corridors of illness. Little Pharma is a Dantean journey from the depths of an institution, and of a pervading personal dread, to a renewed celebration of human contact, the body, and the giddy, terrifying excitement of ongoing life.

Author: Gerald Posner
Publisher: Simon and Schuster
ISBN: 1501152033
Category : Business & Economics
Languages : en
Pages : 816

View

Book Description
"Exorbitant prices for lifesaving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on prescription opioids have caused many to lose faith in pharmaceutical companies. Now, Americans are demanding national reckoning with a monolithic industry. In Pharma, award-winning journalist and New York Times best-selling author Gerald Posner uncovers the real story of the Sacklers, the family that became one of America's wealthiest from the success of OxyContin, their blockbuster narcotic painkiller at the centure of the opioid crisis. The unexpected twists and turns of the Sakler family saga are told against the startling chronicle of a powerful industry that sits at the intersection of public health and profits. Pharma reveals how and why American drug companies have put earnings ahead of patients"--

Author: Ben Goldacre
Publisher: Macmillan
ISBN: 0865478066
Category : Business & Economics
Languages : en
Pages : 479

View

Book Description
Argues that doctors are deliberately misinformed by profit-seeking pharmaceutical companies that casually withhold information about drug efficacy and side effects, explaining the process of pharmaceutical data manipulation and its global consequences. By the best-selling author of Bad Science.

Author: Jennifer Shaw
Publisher:
ISBN: 9780615423470
Category : Fiction
Languages : en
Pages : 148

View

Book Description
Memoir of a pharmaceutical sales representative. An insider's expose of the extraordinarily corrupt pharmaceutical business. A series of honest, funny and disturbing short vignettes. The companies go to extremes having their attractive young reps do whatever it takes to convince doctors to push their prescription drugs and vaccines.

Author: Donald W. Light
Publisher: Springer
ISBN: 1137374330
Category : Social Science
Languages : en
Pages : 282

View

Book Description
Drawing on key concepts in sociology and management, this history describes a remarkable institute that has elevated medical research and worked out solutions to the troubling practices of commercial pharmaceutical research. Good Pharma is the answer to Goldacre's Bad Pharma: ethical research without commercial distortions.

Author: Peter Gotzsche
Publisher: CRC Press
ISBN: 1908911123
Category : Medical
Languages : en
Pages : 251

View

Book Description
PRESCRIPTION DRUGS ARE THE THIRD LEADING CAUSE OF DEATH AFTER HEART DISEASE AND CANCER. In his latest ground-breaking book, Peter C Gotzsche exposes the pharmaceutical industries and their charade of fraudulent behaviour, both in research and marketing where the morally repugnant disregard for human lives is the norm. He convincingly draws close co

Author: Mickey C. Smith
Publisher: CRC Press
ISBN: 1000263657
Category : Business & Economics
Languages : en
Pages : 433

View

Book Description
Pharmaceuticals constitute a relatively small share of the total Health Care expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford Health Care. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, and support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall Health Care system. The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to Health and Health Care, and its dual and often conflicting priorities of affordability and innovation, as well as the various Private and Public Policy initiatives directed at the sector. Everyone is affected by Big Pharma and the products they produce. At the Drug store, the physician’s office, in front of the television, in everyday conversations, Drugs are a part of our lives. Society shapes our values toward Drugs and Drugs shape society. ("The Pill" and minor tranquilizers are good examples.) And, of course, the way Congress deliberates and Big Pharma responds has a huge impact on how Drugs affect our lives. This book is well-researched on the subject of the pharmaceutical industry, its struggles with Government, and its relationship to the consumer from the early twentieth century until the present. The Dynamic Tension between the three participants – Government, Big Pharma, and the People – is described and explained to lead to an understanding of the controversies that rage today. The author describes how the Government, its many investigatory efforts, and the ultimate legislative results affect the industry and the consequences of their activities are explored in light of their effects on other players, including the patients and consumers who rely on both Government and Big Pharma for their well-being and who find sometimes unexpected consequences while giving special attention to the attitudes, beliefs, and misadventures of less-than-optimal Drug use. Stakeholders are identified with physicians as a major focus, as well as describing the significance of prescriptions as social objects and the processes by which physicians make choices on behalf of their patients. The author ties it all together with how Big Pharma affects and is affected by each of these groups. The author utilizes his 50-plus years’ experience as an academic, practicing pharmacist, and Big Pharma employee to describe the scope of the pharmaceutical industry and how it affects us on a daily basis, concluding with an inside look at Big Pharma and how regulations, marketing, and the press have affected their business, both good and bad.

Author: Donald L. Drakeman
Publisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241

View

Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--

Author: Samuel D. Lamptey
Publisher: Troubador Publishing Ltd
ISBN: 1848767846
Category : Business & Economics
Languages : en
Pages : 105

View

Book Description
From Pharma to Device Sales is a concise, straight to the point pocket guide, enabling pharmaceutical sales people to move into the medical device sales arena. There is no other book available that explores how to successfully change industries. This guide has valuable insights from recent personal experiences, up-to-date material and useful statistics – to ensure a successful industry transition. Making the switch from pharmaceutical sales to medical devices can be an uphill struggle. Are you in pharmaceutical sales looking to cross over? Have you ever wondered what selling medical devices is really like? Do you know the vital differences between selling drugs and devices? Do you want to know the typical mistakes pharmaceutical sales people make at interviews and learn how to avoid such pitfalls? This book will provide all these answers and much more! From Pharma to Device Sales is a unique, concise and inspirational book. Whatever stage you are at in your pharma career, this is a must read.

Author: Katherine Eban
Publisher: HarperCollins
ISBN: 0063054108
Category : Medical
Languages : en
Pages : 512

View

Book Description
A NEW YORK TIMES BESTSELLER New York Times 100 Notable Books of 2019 New York Public Library Best Books of 2019 Kirkus Reviews Best Health and Science Books of 2019 Science Friday Best Books of 2019 New postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.